Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Neumann

Showing results (331-340 of 404) with videos related to

Pageof 41
Sort By:
Antimicrobial Agents and Chemotherapy|November 7, 2007
Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivityHelen Cooksley, Shilpa Chokshi, Yafit Maayan, et al.
Journal of Viral Hepatitis|August 27, 2010
Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patientsE S A Araújo, H Dahari, A U Neumann, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trialS Kasper, E Elez, U Neumann, et al.
Transplantation Proceedings|March 20, 1999
Quadruple induction therapy including antithymocyte globulin or interleukin-2 receptor antibody or FK 506-based induction therapy after liver transplantationR Lohmann, J M Langrehr, J Klupp, et al.
Journal of Virology|October 10, 1998
Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1L Zhang, T He, Y Huang, et al.
Hepatology (Baltimore, Md.)|December 26, 2006
Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6Esther Lukasiewicz, Kristoffer Hellstrand, Johan Westin, et al.
Current Biology : CB|July 26, 2022
Ancient Yersinia pestis and Salmonella enterica genomes from Bronze Age CreteGunnar U Neumann, Eirini Skourtanioti, Marta Burri, et al.
Hepatology (Baltimore, Md.)|February 27, 2010
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis CGalia Askarieh, Asa Alsiö, Paolo Pugnale, et al.
Clinical Transplantation|August 1, 1998
A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantationJ M Langrehr, M Glanemann, O Guckelberger, et al.
Transplantation Proceedings|November 20, 1997
Liver transplantation in HBsAg+ patients with postoperative immunoprophylaxisJ M Langrehr, O Guckelberger, U Neumann, et al.
Pageof 41

Showing results (331-340 of 404) with videos related to

Sort By:
Pageof 41
Antimicrobial Agents and Chemotherapy|November 7, 2007
Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivityHelen Cooksley, Shilpa Chokshi, Yafit Maayan, et al.
Journal of Viral Hepatitis|August 27, 2010
Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patientsE S A Araújo, H Dahari, A U Neumann, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trialS Kasper, E Elez, U Neumann, et al.
Transplantation Proceedings|March 20, 1999
Quadruple induction therapy including antithymocyte globulin or interleukin-2 receptor antibody or FK 506-based induction therapy after liver transplantationR Lohmann, J M Langrehr, J Klupp, et al.
Journal of Virology|October 10, 1998
Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1L Zhang, T He, Y Huang, et al.
Hepatology (Baltimore, Md.)|December 26, 2006
Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6Esther Lukasiewicz, Kristoffer Hellstrand, Johan Westin, et al.
Current Biology : CB|July 26, 2022
Ancient Yersinia pestis and Salmonella enterica genomes from Bronze Age CreteGunnar U Neumann, Eirini Skourtanioti, Marta Burri, et al.
Hepatology (Baltimore, Md.)|February 27, 2010
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis CGalia Askarieh, Asa Alsiö, Paolo Pugnale, et al.
Clinical Transplantation|August 1, 1998
A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantationJ M Langrehr, M Glanemann, O Guckelberger, et al.
Transplantation Proceedings|November 20, 1997
Liver transplantation in HBsAg+ patients with postoperative immunoprophylaxisJ M Langrehr, O Guckelberger, U Neumann, et al.
Pageof 41